Stool Gas Profiles Distinguish IBD — and Improve with Treatment

If inflammatory bowel disease (IBD) changes the chemistry of stool, does that chemistry return to normal when the disease is treated? This 2013 study tested both halves of the question.

What the researchers did

The team analyzed stool from 87 people: healthy volunteers and patients with Crohn’s disease, ulcerative colitis, or irritable bowel syndrome. Using a lab technique that captures the volatile compounds released from stool (solid-phase microextraction with GC-MS), they profiled each sample’s gas chemistry. Patient samples were collected both before and after clinical treatment, then compared statistically.

What they found

• Crohn’s disease stood out, with significantly elevated indole and ester derivatives of short-chain fatty acids compared with every other group.
• Indole and phenol were also raised in ulcerative colitis and IBS, though not to a statistically significant degree.
• After treatment, the volatile profiles of patients shifted back toward those of healthy controls.

“Crohn’s disease samples showed significant elevations in the concentrations of ester and alcohol derivates of short-chain fatty acids and indole compared with the other groups.”

“After treatment, the levels of many of the VOCs were significantly reduced and were more similar to those concentrations in healthy controls.”

Why it matters

The treatment-response finding is the key takeaway. Because the stool’s chemical signature changes as disease activity changes, it behaves like a dynamic, longitudinal signal rather than a permanent label. That supports the broader vision of tracking gut health over time through the chemistry the gut produces — while remaining clear that detailed compound-by-compound diagnosis still requires laboratory tools and clinical care.